ETON Eton Pharmaceuticals, Inc.
Stock · NasdaqGM · United States · Healthcare · US29772L1089
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Eton Pharmaceuticals, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
56.46 USD
+19.75%
52-week range
14.27 – 66.37
Dividend yield—
Market cap1.6B
NowoTrade score
68 Grade A
Price history
Daily prices in USD.
Updated 08 Nov 2026 14:54. Information, not advice.
Results
Next results
25 Mar 2027
in 137 days · 17:00 · estimate 0.59
Last results
0.50 vs 0.37 estimated
05 Nov 2026 · Beat +35.1%
Beat the estimate
5 of 12
6 missed · 1 in line
Average surprise
-65.7%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 25 Mar 2027 17:00 | 0.59 | — | — | Upcoming |
| 05 Nov 2026 16:00 | 0.37 | 0.50 | +35.1% | Beat |
| 13 Aug 2026 16:00 | 0.19 | — | — | — |
| 14 May 2026 16:00 | 0.14 | 0.14 | 0.0% | In line |
| 19 Mar 2026 16:00 | 0.20 | 0.19 | -5.0% | Miss |
| 06 Nov 2025 16:00 | 0.16 | 0.04 | -75.0% | Miss |
| 07 Aug 2025 16:00 | 0.02 | 0.03 | +28.6% | Beat |
| 13 May 2025 16:00 | 0.05 | -0.06 | -212.5% | Miss |
| 18 Mar 2025 07:00 | — | -0.03 | -800.9% | Miss |
| 12 Nov 2024 16:00 | -0.01 | 0.02 | +300.0% | Beat |
| 08 Aug 2024 16:00 | -0.07 | -0.12 | -71.4% | Miss |
| 09 May 2024 16:00 | -0.07 | -0.03 | +57.1% | Beat |
| 14 Mar 2024 16:00 | -0.04 | -0.09 | -125.0% | Miss |
| 09 Nov 2023 16:00 | -0.10 | -0.02 | +80.0% | Beat |
| 10 Aug 2023 16:00 | -0.09 | 0.18 | +300.0% | Beat |
| 11 May 2023 16:00 | -0.14 | -0.10 | +28.6% | Beat |
| 16 Mar 2023 16:00 | 0.01 | 0.04 | +300.0% | Beat |
| 10 Nov 2022 16:00 | -0.15 | -0.12 | +20.0% | Beat |
| 11 Aug 2022 16:00 | 0.03 | -0.06 | -300.0% | Miss |
| 12 May 2022 16:00 | -0.08 | -0.21 | -162.5% | Miss |
| 16 Mar 2022 16:00 | 0.05 | 0.04 | -20.0% | Miss |
| 15 Nov 2021 16:00 | -0.13 | -0.24 | -77.8% | Miss |
| 16 Aug 2021 14:00 | -0.14 | -0.10 | +27.4% | Beat |
| 13 May 2021 16:00 | 0.19 | 0.19 | 0.0% | In line |
| 16 Mar 2021 16:00 | -0.26 | -0.29 | -9.4% | Miss |
| 12 Nov 2020 17:00 | -0.25 | -0.31 | -22.4% | Miss |
| 12 Aug 2020 16:00 | -0.26 | -0.23 | +11.5% | Beat |
| 14 May 2020 16:00 | -0.23 | -0.50 | -112.8% | Miss |
| 05 Mar 2020 16:00 | -0.34 | -0.15 | +55.9% | Beat |
| 14 Nov 2019 16:00 | -0.24 | -0.28 | -16.7% | Miss |
| 06 Aug 2019 16:00 | -0.28 | -0.18 | +34.6% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 80M | +104.9% | -4.6M | -5.8% | -0.17 | -13.3% | 10.2M |
| 2024 | 39M | +23.3% | -3.8M | -9.8% | -0.15 | -275.0% | -9M |
| 2023 | 31.6M | +48.9% | -936K | -3.0% | -0.04 | +88.9% | 6M |
| 2022 | 21.3M | — | -9M | -42.4% | -0.36 | — | 2M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 27 Aug 2026 | 62.50 | 63.26 | 61.88 | 62.67 | +0.08% | 445,900 | |
| 26 Aug 2026 | 63.60 | 63.60 | 61.03 | 62.62 | -0.68% | 443,100 | |
| 25 Aug 2026 | 64.55 | 65.50 | 62.00 | 63.05 | -2.14% | 536,600 | |
| 24 Aug 2026 | 63.90 | 66.37 | 62.90 | 64.43 | +1.51% | 801,500 | |
| 21 Aug 2026 | 59.76 | 64.00 | 59.76 | 63.47 | +5.94% | 640,200 | |
| 20 Aug 2026 | 60.99 | 62.58 | 59.59 | 59.91 | -2.55% | 586,500 | |
| 19 Aug 2026 | 63.55 | 63.83 | 60.06 | 61.48 | -3.07% | 608,800 | |
| 18 Aug 2026 | 61.10 | 63.56 | 60.00 | 63.43 | +2.75% | 872,400 | |
| 17 Aug 2026 | 59.15 | 62.87 | 56.65 | 61.73 | +4.88% | 1,284,900 | |
| 14 Aug 2026 | 54.93 | 59.79 | 53.01 | 58.86 | +44.26% | 2,318,200 | |
| 13 Aug 2026 | 42.11 | 43.19 | 40.66 | 40.80 | -1.88% | 696,900 | |
| 12 Aug 2026 | 41.99 | 43.18 | 41.18 | 41.58 | -1.12% | 463,100 | |
| 11 Aug 2026 | 43.60 | 43.60 | 40.61 | 42.05 | -3.71% | 584,400 | |
| 10 Aug 2026 | 44.50 | 45.35 | 43.12 | 43.67 | -2.09% | 370,000 | |
| 07 Aug 2026 | 46.09 | 46.60 | 44.55 | 44.60 | -3.42% | 278,000 | |
| 06 Aug 2026 | 47.36 | 47.36 | 44.40 | 46.18 | +0.46% | 532,200 | |
| 05 Aug 2026 | 47.97 | 48.39 | 45.45 | 45.97 | +0.31% | 388,900 | |
| 04 Aug 2026 | 45.09 | 46.11 | 44.99 | 45.83 | +1.53% | 341,800 | |
| 03 Aug 2026 | 46.52 | 46.55 | 43.49 | 45.14 | -2.76% | 470,700 | |
| 31 Jul 2026 | 49.09 | 49.09 | 46.01 | 46.42 | -5.32% | 484,800 | |
| 30 Jul 2026 | 47.08 | 49.21 | 46.75 | 49.03 | +1.87% | 603,900 | |
| 29 Jul 2026 | 46.57 | 50.18 | 46.55 | 48.13 | +3.15% | 698,100 | |
| 28 Jul 2026 | 43.58 | 47.16 | 42.92 | 46.66 | +10.28% | 890,900 | |
| 27 Jul 2026 | 42.73 | 43.84 | 42.06 | 42.31 | -0.66% | 365,400 | |
| 24 Jul 2026 | 44.14 | 44.55 | 42.39 | 42.59 | -3.51% | 385,700 |
Page 3 of 51
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Why Eton Pharmaceuticals Stock Is Up 19.7% And What's Next (opens in a new tab) Simply Wall St. · 07 Nov 2026 13:11
- Canaccord Genuity Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $80 (opens in a new tab) Benzinga · 06 Nov 2026 15:44
- HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $80 (opens in a new tab) Benzinga · 06 Nov 2026 09:24
- Eton Q3 Earnings Call Highlights Growth and Pipeline Expansion (opens in a new tab) Zacks · 06 Nov 2026 08:27
- Eton Pharma (ETON) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 06 Nov 2026 07:29
- Eton Pharmaceuticals Inc (ETON) (Q3 2026) Earnings Call Highlights: Record Revenue, Raised ... (opens in a new tab) GuruFocus.com · 06 Nov 2026 07:22
- Eton Pharmaceuticals Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 06 Nov 2026 06:14
- Eton Pharmaceuticals, Inc. (ETON) Q3 Earnings and Revenues Surpass Estimates (opens in a new tab) Zacks · 06 Nov 2026 00:00
- Eton Pharmaceuticals (NASDAQ:ETON) Surges on Q3 Beat and Raised Guidance (opens in a new tab) ChartMill · 05 Nov 2026 23:38
- Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results (opens in a new tab) 05 Nov 2026 21:05
- Eton Pharmaceuticals, Inc. (ETON) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 05 Nov 2026 21:04
- Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal Tolerability (opens in a new tab) 05 Nov 2026 21:01
- Eton Pharmaceuticals Q3 2026 Earnings Call Transcript (opens in a new tab) Benzinga · 05 Nov 2026 18:34
- Eton Pharmaceuticals FY2026 Revenue expected to be more than $175.000M vs $149.702M Est (opens in a new tab) Benzinga · 05 Nov 2026 17:22
- Eton Pharmaceuticals Announces Its ET-700 Zing Acetate Formulation Shows Lower Rate Of Drug Related Adverse Events In Pilot Trial Than GALZIN; No Serious Adverse Events Seen (opens in a new tab) Benzinga · 05 Nov 2026 17:20
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 47.15 USD
- Market cap
- 1.6B
- Exchange
- NasdaqGM
- Country
- United States
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 16.7 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 16.4 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 4.4 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- The last full year was a loss
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 6 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 36.66× | Weak | 30.65× |
| P/E (forward) | 17.08× | Fair | 14.89× |
| Price / book | 18.73× | Weak | 3.81× |
| Price / sales | 11.54× | Weak | 3.19× |
| EV / EBITDA | 32.51× | Weak | 12.63× |
| Free cash flow yield | 0.9% | Weak | 2.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 71.2% | Good | 58.6% |
| Operating margin | 40.5% | Good | 7.8% |
| Net margin | 35.3% | Good | 2.8% |
| Return on equity | 90.6% | Good | 5.7% |
| Return on assets | 21.1% | Good | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 55.5% | Good | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.28× | Good | 0.48× |
| Net debt / EBITDA | -0.64× | Good | 1.6× |
| Current ratio | 1.79× | Good | 2.39× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow ETON and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.